ELDN - חוב כולל להון Eledon Pharmaceuticals, Inc

Eledon Pharmaceuticals (ELDN) is recognized as an immunology expert, developing treatments to extend recipient longevity. The company is developing innovative drugs that could replace legacy therapy protocols. Business growth relies on partnerships with transplant centers to accelerate testing. This market valuation chart on GURU.Markets shows that the debt-to-equity ratio is 0.01.

This ratio measures the proportion of borrowed funds in the financing structure relative to equity. Investors utilize this leverage to assess financial stability and bankruptcy risks. By analyzing the total debt-to-equity ratio, one can determine the company's degree of dependence on creditors. For Eledon Pharmaceuticals (ELDN), this balance is critical, as the development of tegoprubart requires significant expenditures. A high debt load could limit the capacity to implement innovative antibody therapy.